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Abstract: Despite advances in malignant pleural mesothelioma therapy, life expectancy of affected
patients remains short. The limited efficiency of treatment options is mainly caused by inter- and
intra-tumor heterogeneity of mesotheliomas. This diversity can be observed at the morphological
and molecular levels. Molecular analyses reveal a high heterogeneity (i) between patients; (ii) within
different areas of a given tumor in terms of different clonal compositions; and (iii) during treatment
over time. The aim of the present review is to highlight this diversity and its therapeutic implications.
Keywords: mesothelioma; inter-tumor heterogeneity; temporal intra-tumor heterogeneity;
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1. Introduction
Malignant Pleural Mesothelioma (MPM) is a rare and aggressive neoplasm arising from a layer of
mesothelial cells lining the pleura. The main cause of MPM is exposure to asbestos fibers that provoke
constant inflammation and malignant transformation of mesothelial cells by direct mitotic spindle
interference, reactive oxygen species release, and macrophage attraction [1]. The latency of the cancer
is about 40 years, but once diagnosed, the life expectancy without treatment is less than 12 months [2].
The treatment usually includes chemotherapy followed by surgery, which can prolong the median
survival to 22 months [3]. However, the chemotherapy is only effective in approximately 30–40% of
the patients [4]. In addition, an effective alternative treatment or second line treatment has not yet
been established [5]. With the exception of a recent phase three trial combining Bevacizumab with
the standard cisplatin and pemetrexed chemotherapy in newly diagnosed MPM [6], clinical trials
aiming for a targeted therapy approach in common cancer signaling pathways have not resulted in
a better overall survival (OS) [7]. These studies stress the need for new biomarkers to predict the
clinical response to chemotherapy as well as to find new possible targets for alternative therapy
approaches. The search for new treatment options is complicated by the genetic composition of the
tumor. Mutations are mainly found in tumor suppressors (COSMIC [8]), but common oncogenes
such as PI3K, EGFR, and VEGFR are, if any, rarely found to be mutated in MPM, which limits the
choice of targeted inhibitors. Although studies have shown that loss of tumor suppressors, such as
NF2 and CDKN2A/p16, lead to upregulation of associated oncogenic pathways, the translation of this
knowledge into effective treatments has not yet occurred.
The mechanisms underlying the poor response of patients with MPM to a wide range of
therapeutic interventions is still unknown. One reason for the inefficacy of the treatment regimens is
the molecular inter-tumor heterogeneity, describing the diverse mutational (referred to as “genetic”
in this review), epigenetic, expressional, and macroscropic (summarized as “phenotypical”) changes
between patients. Many mutations, such as in EGFR or TP53, are undetectable in the majority of MPM
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cases (COSMIC [8]). In contrast to non-small cell lung cancer [9], the relatively low number of MPM
cases combined with the low prevalence of drug-targetable EGFR mutations in MPM compromises the
investigation and use of selective EGFR inhibitors in the treatment of mesothelioma.
Adding to the complexity that arises due to inter-tumor heterogeneity, patient tumors also
display intra-tumor heterogeneity. The existence of several tumor clones and subclones within
one tumor sample of the same patient significantly limits the ability to devise logical treatment
strategies. Intra-tumor heterogeneity appears during the course of the disease (temporal intra-tumor
heterogeneity) as well as in different locations within the tumor at one time point (spatial intra-tumor
heterogeneity).
Histologically, temporal and spatial intra-tumor heterogeneity in MPM manifests with
a morphological spectrum, ranging from epithelioid to sarcomatoid tumors with the biphasic subtype
containing a combination of both epithelioid and sarcomatoid components, each constituting at least
10% of the tumor. Adding to the complexity of histological subtyping, morphological biomarkers in
epithelioid MPM, including nuclear atypia and number of mitoses, have been used to determine a total
score which independently correlates with overall survival [10]. This further supports the existence
of tumor heterogeneity, even within morphological well-defined subgroups of MPM. Furthermore
some MPMs show a change of histology during the course of the disease, which represents temporal
heterogeneity [11]. Besides this microscopic diversity, an increasing number of publications highlight
the importance of genetic intra-tumor heterogeneity for therapeutic resistances in several cancer
types [12]. Until now, this phenomenon has attracted little attention in MPM.
The aim of the present review is to highlight the different forms of heterogeneity in MPM with
emphasis on the genetic and phenotypic intra-tumor heterogeneity. We summarize evidence of the
spatial and temporal evolution of MPM, during the treatment with standard of care chemotherapy,
and discuss the implications of heterogeneity on treatment decisions.
2. Inter-Tumor Heterogeneity
MPMs are known to have a high degree of molecular inter-tumor heterogeneity. In terms of
genetic alterations, MPM generally displays a low number of mutations and recurrent mutations
compared to other cancers [13]. The genes that were reported to be most often mutated are
BAP1 and NF2. Other commonly detected SNVs are found in LATS1/2, TP53, and TERT [14,15].
More prominent than SNVs are large chromosomal aberrations, which are thought to arise from
direct interference with asbestos fibers or general chromosomal instability due to dysfunctional DNA
damage response [1]. Chromosomal losses are the most frequent alterations in MPM, mostly affecting
the chromosomal arms 3p, 9p, and 22q, where, amongst others genes, BAP1, CDKN2A, and NF2 are
located, respectively [8,16,17]. A high number of patients even harbor homozygous deletions of the
CDKN2A region [18].
Despite these common alterations, the composition and gene locations of the mutations vary
considerably between patients. A large sequencing study by Lo Iacono and colleagues, using 123 FFPE
samples, sequenced 50 genes using the AmpliSeq Cancer Hotspot Panel plus another custom-designed
amplicon panel covering the exons of the NF2 and BAP1 genes [19]. Although the authors reported
a higher number of mutations clustering in exon 13 and 17 of the BAP1 gene, which are the two largest
exons, it did not seem that those were common hotspots for BAP1 mutations (COSMIC [8]); there was
more of an enrichment found in the N-terminal Ubiquitin Hydrolase domain (COSMIC [8]). Another
study by Guo et al. compared 22 MPM tumor samples with matched blood samples using exome
sequencing [13]. In total, they detected 490 somatic protein-altering mutations of which 477 were
private alterations. Another working group led by Mäki-Nevala also performed exome-sequencing on
21 patients (two of them with peritoneal mesothelioma) and only found two non-private mutations
in TTLL6 and MRPL1 occurring in two asbestos-exposed MM patients [20]. Ugurluer and colleagues
as well as Kato and colleagues [21,22] both used a large gene panel covering 236 genes. Both groups,
analyzing 11 [21] and 42 [22] mesothelioma patients, also failed to find any non-private alterations.
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Other groups working with smaller gene panels [14,23] also showed only private mutations. The results
from these publications clearly illustrate that, in contrast to e.g., the L858R mutation in EGFR in lung
cancer [24], there are no commonly mutated amino acid positions or “hotspot” regions in any of the
genes tested.
In summary, these molecular analyses highlight the high inter-patient variability of locations and
compositions of mutational patterns. This heterogeneity compromises the use of targeted therapy for
mesothelioma patients and necessitates a personalized approach (Table 1). Clinical trials inhibiting
for example the EGFR receptor in MPM patients using Erlotinib (NCT01592383, NCT00137826,
NCT00039182), Gefitinib (NCT00787410, NCT00025207), Vandetanib (NCT00597116), or Cetuximab
(NCT00996567) did not reveal any beneficial effects of the treatment. Although the mutational rate
of EGFR is below 1% in MPM (COSMIC [8]), the rationale of those studies were the overexpression
of EGFR which is found in over 50% of cases [25,26]. Destro and colleagues stained tumor tissue of
61 patients, whereby positive staining in 0–10% of tumor cells was regarded as negative expression,
in 10–50% as low, and in >50% as high [25]. Only 9/61 (14.8%) showed a high EGFR expression,
whereas 41.0% (21/61) only showed a staining in less than 50% of tumor cells, indicating that only
a subpopulation of tumor cells overexpress EGFR. Enomoto and colleagues also stained 22 MPM
cases, setting the thresholds for score 1+ for <5% positive tumor cells, score 2+ for 5–50% and score
3+ for >50% [26]. They scored 50% (11/22) of tumors as 3+ expression. Based on the assumption that
high EGFR expression predicts the success of EGFR inhibiting drugs such as Erlotinib, detection of
strong positive staining should be used as inclusion criteria in future studies. However, it was already
shown that in many cancers, EGFR expression levels are not associated with a positive response
to targeted therapy [27]. This was also documented in MPM by Garland and colleagues assessing
EGFR expression in 57 patients with MPM [28]. A score of 0 was given for negative staining, score 1
for weak and focal staining, score 2 for positive and homogenous staining and score 3 for intense
staining. In their cohort, 75% of the tumors stained score 2 or 3 for EGFR. However, no objective
clinical responses to Erlotinib treatment was noted. Similar results were shown using Gefitinib [29]
and Cetuximab [30], which strongly indicates that high EGFR expression cannot be used to predict
response to EGFR inhibitors in patients with mesothelioma.
In our sequencing studies (Oehl et al., manuscript in preparation), we could see EGFR mutations
at low allele frequency in the tissues, indicating a subclonal origin. Further, EGFR staining, as described
above, often shows a focal pattern. Both findings suggest that there could be, additionally to
the inter-tumor variability, a high intra-tumor heterogeneity additively influencing the outcome
of anti-EGFR treatments in a negative way.
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Table 1. Selection of finished studies using targeted therapy approaches in malignant pleural mesothelioma (MPM). The mutational rate in MPM was taken from the
cosmic database. Data on expression were taken from indicated references.
Target Drug Study Year ofCompletion Status # Patients Results Marker
Mutational
Rate in MPM Expression in MPM
NCT00770120 2014 completed 61 primary endpoint not reached
mTor Everolimus NCT01024946 2012 completed 11 none published
FAK Defactinib NCT01870609 2016 terminated 344 lack of efficiency
NF2 (Merlin) 17% (105/629) 4% [31]–8% [32] negative
ALK1 PF-03446962 NCT01486368 2015 completed 17 primary endpoint not reached ALK 0% (1/343) 0% [33]–20% [34] positive
Erlotinib NCT00039182 2007 completed 55 primary endpoints not reached
EGFR Cetuximab NCT00996567 2015 completed 22 primary endpoint not reached EGFR 1% (8/652)
15% [25], 50% [26], 75% [28] high
c-Met Tivantinib NCT01861301 2015 terminated 18 lack of efficiency MET 1% (3/448) 17% [35]–40% [36] high
Background color highlights groups of studies that employed the same marker for patient stratification.
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3. Spatial Intra-Tumor Heterogeneity
3.1. Spatial Genetic Heterogeneity
MPM is known to show intrinsic therapy resistances and is so far non-curable. The high number
of non-responders to chemotherapy [4] as well as the frequent recurrences of the disease [37,38] suggest
a substantial degree of resistant clones within an MPM patient. In silico modeling of spatial tumor
growth suggests that the number of driver gene mutations, as well as the speed of cell turnover, greatly
influences the degree of heterogeneity within a tumor [39]. Interestingly, the model proposed by
Waclaw et al. shows that fewer driver mutations and a slow cell turnover lead to an increased level of
heterogeneity [39]. Given that mesothelioma is supposed to develop over many years, the replication
rate is in most cases quite low, indicating that there should be a very high degree of molecular diversity
within the tumor.
Indeed, Comertpay and colleagues assessed the clonality of malignant mesothelioma in 14 female
patients using a HUMARA assay [40]. This assay is based on X-chromosome inactivation by
methylation and the HUMARA gene which is located on the X-chromosome. This gene encodes for
the Human Androgen Receptor and harbors a varying number of CAG repeats, which usually differs
between the maternal and paternal allele. One allele gets deactivated in healthy females; therefore,
if a cancer was of monoclonal origin, only one allele would be detected in the tumor. However, when
using the HUMARA assay on MPM tissue, Comertpay et al. detected paternal and maternal HUMARA
alleles within most of the tumors, indicative of a polyclonal origin of MPM.
As described above, a common molecular alteration is the homozygous deletion of CDKN2A (p16)
on chromosome 9. However, when measured by fluorescent in-situ hybridization (FISH) on tumor
tissue, it is well known that the homozygous deletion cannot be detected in all cells of the tumor.
Indeed, the status of the CDKN2A gene is highly variable, with no detectable loss, hemizygous losses
and homozygous losses of CDKN2A within the same tumor. Defining a tumor as “homozygously
deleted for CDKN2A” therefore requires defined cut-offs, such as 14.4% in a study by Wu et al. that
compared the homozygous deletion patterns of CDKN2A between sarcomatoid mesothelioma and
fibrous pleuritis [41]. These detections of non-homogenous deletions of CDKN2A suggest that besides
the polyclonal origin, several genetic subclones might also exist within one tumor.
However, the only study so far describing genetic spatial heterogeneity was recently conducted
by Kiyotani and colleagues [42]. From the surgical specimens of six MPM patients, they extracted
DNA and RNA from fresh frozen tissue from three different locations within the tumor, namely from
anterior, posterior, and diaphragm positions. They then conducted whole-exome sequencing, resulting
in 19–47 non-synonymous mutations per sample. When looking at the SNVs that were detected at the
three different locations within one patient, they found clearly distinct mutational patterns. Comparing
the allele frequencies of these mutations, they detected some high variant allele frequency mutations
in every examined location of the respective tumor, indicative of mutations of early clonal origin.
Moreover, they saw a high degree of intra-tumoral spatial heterogeneity represented by varying
amounts of subclonal fractions. The addition of TCRβ sequencing data and immune-related gene
expression analysis revealed that this heterogeneity also extends to the immune microenvironment.
3.2. Spatial Phenotypic and Tumor Microenvironment Heterogeneity
As mentioned above, tumor heterogeneity is not only described by a heterogeneous genetic
makeup of tumor cells within the same patient. The heterogeneity can also arise from selective
environmental pressure such as nutrient, oxygen, tumor stroma, and immune microenvironment
that can induce tumor heterogeneity by altering their phenotypes. This selective pressure of the
microenvironment can govern the tumor phenotype by altering signaling pathways, regulating gene
and protein expression. These intra-tumoral differences in the environment could result in therapy
resistances [43]. To support this idea, it has been clearly demonstrated that hypoxic tumors are
more resistant to chemotherapy and radiotherapy [44]. A recent study visualized tumor hypoxia by
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non-invasive imaging, [F-18] fluoromisonidazole (FMISO) PET-CT, and demonstrated that MPM has
a visible area of hypoxia, predominantly in bulky tumor masses [45]. Thus, tumor cells in different
regions of the tumor nodule may respond differentially to treatment. In view of immunotherapeutic
approaches, for example using PD-1 or PD-L1 blocking antibodies, the heterogeneity of PD-L1 protein
levels between primary and metastatic sites was recently studied in 64 MPM patients [46]. It was shown
that PD-L1 expression, measured by immunohistochemical staining, was discordant in up to 31% of
the cases (depending on the reviewer), which pronounces the limits of successful immunotherapy
using anti-PD-L1 antibodies in mesothelioma. However, as seen in the example of the focal EGFR
staining described above, the heterogeneity of protein expression is not only found in primary tumors
and metastases but it also occurs within different regions within the same primary tumor. For example,
loss of BAP1 expression in biphasic MPM can only be found in the epithelioid part of the tumor
(Figure 1), whereas BAP1 is retained in the sarcomatoid component. The different expression profiles
in different parts of the tumor could be related to the genetic or epigenetic background and require
further investigation.
Although some studies indicate that genetic, phenotypic, and microenvironmental intra-tumor
heterogeneity in MPM exist, our knowledge is still limited. More studies assessing spatial MPM
heterogeneity are needed to improve our understanding of the pathophysiological mechanisms
underlying MPM and to develop new treatment approaches that circumvent the impact of
intra-tumor heterogeneity.
However, the question remains, which mechanisms lead to the development of spatial
heterogeneity in MPM? A widely accepted theory (besides the cancer stem cell (CSC) theory which we
will discuss later in this review) is that of clonal tumor evolution [47]. Hereby, a tumor accumulates
somatic mutations and chromosomal aberrations in a stepwise manner. Some of these alterations are
so-called “driver mutations”, conferring a fitness advantage to the respective clones and leading to the
development of several subclones, which are ultimately detected as spatial heterogeneity (Figure 2).
Therefore, the spatial heterogeneity within a tumor can be seen as the result of a temporal heterogeneity,
which we will discuss in the next chapters.
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Figure 1. Morphological and immunohistochemical heterogeneity in mesothelioma. (A) Biphasic
mesothelioma consisting of an epithelioid and sarcomatoid component (H&E stain), highlighted
by a calretinin staining (B) showing a weaker expression in the sarcomatoid proliferation.
(C) Heterogeneous expression of BAP-1 with positive nuclear staining in the sarcomatoid component
and loss of BAP-1 expression in the epithelioid areas of the tumor. All pictures were taken at
10×magnification (scale bar: 100 µm).
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Figure 2. Models of tumor heterogeneity. In the clonal evolution model (upper panel) all cells are
able to replicate (indicated by “R”). Mutations (colored arrows) are gained over time, leading to the
formation of subclones which results in a heterogeneous tumor. In the cancer stem cell (CSC) model
with clonal evolution, only CSCs are able to replicate. However, mutations occurring over time lead to
the formation of additional CSCs.
4. Temporal Intra-Tumor Heterogeneity
Mesothelioma is often diagnosed at an advanced stage due to late onset and non-specific
symptoms. Surgery and cytotoxic chemotherapy, platinum (cis- or carboplatin) plus pemetrexed,
are standard first-line treatment for patie ts with MPM. Nevertheless, the prog osis of MPM remains
poor because of tumor recurrence within a median time of 10–18 months after initia treatment [2].
As d scribed above, tumors can evolve over ime dur ng multiple rou ds of cell division.
The presence of selective pressure such as treatm nt with an anti-cancer drug is an additional factor
driving tumor lonal evolution (Figure 2). This temporal heterogeneity has sever implic ti ns for
treatment decisions, as seen in various cancer entities. For example, a study in medulloblastoma,
revealed that genetic aberrations of recurrent tu or tissues following the treatment with chemotherapy
and radiotherapy diverged from that of diagnostic (treatment naive) tissues. This was due to the
selection of the preexisting subclones that were already present before the treatment [48]. Another
study in breast cancer observed an enrichment of slow proliferating cell populations with different
molecular and biological characteristics following the treatment with chemotherapy, depending on the
subtype of cancer. Employing single cell FISH analysis, they further demonstrated that breast cancer
patients with low genetic heterogeneity responded better to the treatment [49]. To date, there is no
study directly assessing temporal MPM heterogeneity and its implication on treatment outcomes.
4.1. Chemotherapy and Tumor Heterogeneity
Cisplatin and pemetrexed are the common cytotoxic agents given to MPM patients as a first-line
treatment. Cisplatin is a genotoxic drug that induces intrastrand DNA cross-linking, inducing DNA
damage, growth arrest, and cell death [50]. Pemetrexed is a folate antimetabolite that inhibits three
enzymes involved in purine and pyrimidine synthesis. The lack of purine and pyrimidine results in the
inhibition of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis, essential elements
for cell proliferation and survival. Treatment with cisplatin-pemetrexed may eradicate sensitive and
highly proliferative cells, but the resistant c lls remain d can still grow or regrow following the
treatment. Thus, this sel ctive pressur can alt r the c mposition of th tumor cell population and the
extent of tumor heterogeneity following the treatment. Moreover, these cytotoxic agents can cha ge
the biological characteristics of tumor cells. For example, changes in the expression of genes associated
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with both cellular senescence (PAI-1 and IL-6) and a gene identified as a cancer stem cell marker
(Thy-1) were detected in primary MPM cells following exposure to cisplatin-pemetrexed. Moreover,
increased Thy-1 expression was observed in acquired cisplatin pemetrexed resistant cells in vitro [51].
In addition to inducing phenotypical changes, DNA damage caused by cisplatin, if incorrectly repaired,
can generate novel mutations or chromosome alterations, thereby increasing genetic diversity of
tumors. Nonetheless, chemotherapy may generate a novel targetable mutation or cause an enrichment
of targetable mutations that are not detectable prior to the treatment.
Thus, knowing the genetic and phenotypical changes of relapse tumors can be useful for the
selection of effective second line treatment. For MPM, there has been no study assessing the effect of
chemotherapy on the temporal heterogeneity. To study whether the genetic makeup of MPM changes
over the course of treatment and disease progression, we compare the mutation profile of MPM
in tumor tissues collected at three different time points during treatment (pre-chemo, post-chemo,
and recurrence). Preliminary data (Oehl et al., manuscript in preparation), suggests that the genetic
basis of some of the MPM tumors change over the course of treatment with chemotherapy.
Phenotypic changes of MPM tumor cells following the treatment with chemotherapy have
also been observed in some studies. Indeed, the histologic subtype of the tumor changes over the
course of therapy [11]. We also observed protein expression changes of MPM tumors following
the treatment with chemotherapy. In our previous study [52], we compared protein expression of
markers of the PI3K-mTOR pathway namely PTEN, p-mTOR, and p-S6 in matched MPM tissues
pre- and post- cisplatin-based induction chemotherapy. Staining of the tissue microarray (TMA)
revealed a reduction of protein expression of PTEN, p-mTOR, and p-S6 in the tumor tissues following
chemotherapy. A decrease in tumor proliferative activity (Ki-67 expression) and slightly increased
numbers of apoptotic cells (cleaved Caspase-3 staining) were also detected following the treatment.
In another study [53] using the same patient cohort, we observed increased NF2 (Merlin) expression and
decreased Survivin labelling in post chemotherapy treatment tissues (unpublished data). Employing
a cohort of 34 patients with pre- and post- chemotherapeutic tissues available, Sidi et al. demonstrated
that expression of senescence marker genes such as PAI-1 and p21 was significantly increased after
chemotherapy [54].
These studies show that sampling at different time points during MPM treatment might reveal
new potential treatment targets, which were not detectable at the time of diagnosis. Thus, longitudinal
analysis of tumor tissues may be useful for the selection of subsequent effective therapies for
MPM patients.
4.2. MPM Cancer Stem Cell
Cancer stem cells also play a role in tumor heterogeneity. Cancer stem cells represent a small
population of tumor cells that are able to self-renew (Figure 2). Upon cell division, cancer stem cells
give rise to progeny cells that maintain self-renewal properties or differentiate into various cell entities.
It is widely demonstrated that cancer stem cells are commonly resistant to various anti-cancer drugs.
Although the stem cell model remains controversial, cells with stem-cell like properties have been
shown to contribute to tumor heterogeneity and therapy resistance in many solid tumors [55].
Relying on the basis that cancer stem cells express high levels of membrane drug transporter
ABCG2, a study by Kai et al., employed Hoechst 33342 dye efflux assay to identify a MPM stem
cell population [56]. Using this assay, they detected a small subset of cells (side population; SP) that
can exclude Hoechst dye in three MPM cell lines and a transformed mesothelial cell line (MeT-5A)
(number ranging from 0.05–1.32%). Treatment with cisplatin substantially increased the SP fraction
of MPM cells. Interestingly, this SP population expressed higher levels of stem cell related genes
namely BMI1, OCT4, and NOTCH1 compared to non-SP (NSP) cells. However, despite exhibiting
enhanced proliferation in vitro, there was no difference in in vivo tumorigenicity of both SP and NSP
when implanted subcutaneously in NOD/SCID mice. Another study by Frei et al., also employed the
same functional assay (using DyeCycleViolet) to identify SP on MPM cell lines and primary cells [57].
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This study could also detect a small population of SP in all cell lines tested (ranging from 0.2–1%).
Similar to the previous study, there was no difference in tumorigenicity between SP and NSP when
implanted under the renal capsular of NOD/SCID mice. However, when SP cells were sorted from the
in vivo tumor tissues, these tended to be more tumorigenic compared to NSP (although this was not
statistically significant). MPM SP were however more resistant to cisplatin and expressed increased
level of PTCH1, a gene of the sonic hedgehog signaling pathway.
Kim Chul et al. further characterized MPM SP using genome wide DNA methylation profiling
coupled with mRNA expression [58]. This study described increased DNA methylation in CpG
islands, gene flanking, and intragenic regions in SP cells compared to NSP. They identified 1130 genes
differentially expressed in SP compared to NSP, among which, 122 genes are known to be regulated
by aberrant DNA methylation. Importantly, these candidate genes, such as YAP1 and NOTCH2,
are known to play an important role in the maintenance of stem cell and the regulation of differentiation
and development.
High level of ALDH1A has been used as a marker of CSCs. Thus, a study by Shapiro, et al.
identified a CSC population of Merlin (NF2) negative MPM cell lines using the Aldefluor assay [59].
Here, they detected MPM CSCs (Aldefluor + cells) with increased tumor initiating potential compared
to non-CSCs when implanted into immunodeficient mice. Treatment with cisplatin-pemetrexed
increased this CSC population of MPM cell lines while treatment with the FAK inhibitor VS-4718
reduced the number of CSCs in vitro. Using a preclinical patient derived xenograft (PDX) model,
they further demonstrated that treatment with the FAK inhibitor targeting CSC populations was
effective in the control of tumor growth following cisplatin-pemetrexed treatment, that had enriched
the CSC population.
In conclusion, SP displaying CSC characteristics have been identified in MPM cell lines and
primary cells. In a preclinical model, CSCs survive during the treatment with cisplatin and pemetrexed
and thus can give rise to a new generation of tumor cell population and create the diversity of recurrent
tumor clones that differ from tumor at diagnosis. Thus far, all studies isolated potential MPM CSCs
from cell lines, thus more evidence on the existence of CSCs in MPM clinical specimens and their
role in treatment resistant is needed. An important factor when investigating CSCs in MPM is to
take into account the intrinsic self-renewing capacity of mesothelial tissues which is conferred by
mesothelial progenitor cells [60]. Given the heterogeneous and polyclonal nature of MPM, one can
speculate that there exist several MPM CSC clones with different genetic alterations. These can also
stem from clonal evolution of CSCs that acquire mutations over time during disease progression
(Figure 2). This scenario would further increase the complexity of MPM heterogeneity.
5. Implications for Therapy
Results from clinical trials testing targeted treatments in MPM have so far been discouraging.
As illustrated above, one factor responsible for poor treatment outcome is inter-patient variability
in the expression or mutational status of the target molecules. Thus, appropriate predictive markers
for targeted treatments are needed for the design and implementation of clinical studies. Although
stratification of patients regarding to predictive markers is difficult to realize given the low incidence
of MPM, this personalized treatment is probably the only way to overcome the high inter-patient
heterogeneity of the disease.
As discussed above, another level of heterogeneity, namely the intra-tumor heterogeneity
observed on both the genetic and phenotypic level in MPM, is another hurdle for the success of
MPM treatment. MPM tumor may comprise of heterogeneous variants of tumor cells possessing
different levels of chemosensitivity that can affect macroscopic response outcomes. The remaining
chemoresistant cells can progress and reestablish tumor heterogeneity in the relapse tumor.
Cancer stem cells may also play a role in chemoresistance of MPM. Their role in actual tumor
and disease progression, however, remains to be elucidated. If CSCs can be defined in the patient
tumor tissue, they might represent a potent target for therapy approaches to overcome chemotherapy
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resistance of MPM. Intra-tumor heterogeneity is also a major factor that complicates the development
of new targeted agents. Treatment targeting only a small subpopulation of tumor will not be effective,
but targeting the core gene or pathway alteration that are shared across all tumor cells will provide
the most efficient way to eradicate tumors. To address genetic heterogeneity, an obvious approach
would be to model the tumor evolution by either single cell or tumor bulk sequencing to define driving
mutations of early clonal origin. Understanding the pathways behind those mutations could then be
exploited to develop new therapeutic approaches targeting most, if not all, of the tumor cells. However,
using this approach it will be inevitable to monitor the development of the tumor over the course
of treatment, since the probability of selecting resistant clones is quite high, as seen previously for
example in lung adenocarcinoma [61]. This monitoring will further provide important information for
the selection of subsequent effective treatment.
In general, the tracking and multi-level analysis of the tumor tissue implies the need for sufficient
material. This is usually available after surgery (if conducted), but in order to reveal alternative
treatment options prior to or instead of operative interventions and chemotherapy, it will be necessary
to analyze the tissue derived from the diagnostic biopsy. Therefore, it is critical to remove an adequate
amount of tissue.
Furthermore, knowing that MPM is a heterogeneous disease, single-region sampling is unlikely to
reflect the complete genetic and phenotypic landscape of the tumor. Therefore, multi-region sampling
is required in order to determine dominant clones and potential therapy resistant subclones.
Since this approach might be difficult to be carried out in clinics, an alternative option could be the
detection of circulating cell free tumor DNA (ctDNA) in the blood or pleural fluid of MPM patients [62].
In this scenario, ctDNA is a pool of DNA released from tumor cells at different locations thus could
serve as a good representation of genomic heterogeneity. A recent study in colorectal cancer for example
collected plasma samples at different time points during multimodality treatment [63]. They could
show that patients that tested mutation-positive in their ctDNA after chemoradiotherapy or surgery
had an increased risk of recurrence. A previous study by the same group, also in colorectal cancer,
could even show that the median lead time between ctDNA detection and radiological recurrence
was higher than five months [64]. However, both studies relied on the detection of mutations that
were previously found in the primary cancers of the respective patients, and thus could not identify
novel mutations or mutations that were enriched during the treatment course. In order to address this
drawback, other groups like Shu et al. used a panel of 382 cancer-associated genes for sequencing
of ctDNA from various cancer entities and reported several mutations that were not found in the
corresponding primary tumor, probably representing temporal or spatial heterogeneity [65]. A similar
approach using MPM associated genes could be envisioned for the future monitoring of mesothelioma
treatment. New next generation sequencing techniques and improved bioinformatical pipelines hereby
enable the reliable detection of low frequency alleles and possible subclones also in clinical settings [66].
Taken together, intra-tumor heterogeneity and its importance in the treatment of cancer has been
clearly demonstrated in recent years. It is predictable that MPM is a heterogeneous tumor as it takes
30–40 years from asbestos exposure to disease development with the tumor developing on a large
surface of the mesothelial layer lining the thoracic cavity. Nevertheless, there has only been a limited
number of publications addressing the intra-tumor heterogeneity of MPM, an aggressive malignancy
with limited therapeutic options. Thus, more studies are required to dissect different levels of MPM
intra-tumor heterogeneity at different time points during treatment. Clearly, a better understanding of
MPM evolution is essential for designing more effective treatment regimens.
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